Santana RNR, Ungson GMG, Aceves VMA, Sánchez DLE

Language: Spanish
References: 19
Page: 164-168
PDF size: 327.56 Kb.

ABSTRACT

Dupilumab is a completely human monoclonal antibody, which targets the IL-4 receptor, inhibiting it and preventing the differentiation of Th0 lymphocytes into Th2, the pathophysiological mechanism of atopic dermatitis. Benefiting from its use and being one of its approved indications. It’s been seen that this mechanism of action can worsen diseases concomitant to atopic dermatitis, such as alopecia areata, because this inhibition stimulates differentiation towards Th1, however, in some cases of alopecia areata it has been found that they present a profile of Th2 cytokines, sharing a common immunological pathway in case of concomitance, which explains the improvement of both pathologies with the use of dupilumab.
We present a 30-year-old female with a 1-year history of alopecia areata, atopic dermatitis and a good response to dupilumab

REFERENCES

1. Harb H et al., Mechanisms of dupilumab, Clin Exp Allergy 2019; 00:1-10.

2. Taisuke I et al., Understanding the significance of cytokines and chemokinesin the pathogenesis of alopecia areata, Exp Dematol 2020;29(8):726-32

3. Waskiel-Burnat A et al., The role of serum Th1, Th2, and Th17 cytokinesin patients with alopecia areata: clinical implications, Cells 2021;10:3397.

4. Aceves Villalvazo MA y Sánchez-Dueñas LE, Anti-il4 /il-13, terapia biológicaen dermatología, 1ª ed, México, Alfil, 2021, pp. 128-40 .

5. Teraki Y et al., Cytokines in alopecia areata: contrasting cytokine profilesin localized form and extensive form (alopecia universalis), ActaDerm Venereol 1996; 76:421-3.

6. Simpson E et al., The validated investigator global assessment foratopic dermatitis (viga-ad): the development and reliability testing ofa novel clinical outcome measurement instrument for the severity ofatopic dermatitis, J Am Acad Dermatol 2020; 83(3):839-46.

7. Darrigade AS et al., Dual efficacy of dupilumab in a patient with concomitantatopic dermatitis and alopecia areata, Br J Dermatol 2018;179:534-6.

8. Alniemi DT y McGevna L, Dupilumab treatment for atopic dermatitisleading to unexpected treatment for alopecia universalis, jaad CaseRep 2019; 5:111-2.

9. Aszodi N et al., Dupilumab-associated healing of alopecia areata in anatopic dermatitis patient, Dtsch Med Wochensch 2019; 144:602-5.

10. Smogorzewski J et al., Remission of alopecia universalis in a patientwith atopic dermatitis treated with dupilumab, jaad Case Rep 2019;5:116-7.

11. Ludriksone L et al., Patienten mit abheilung einer alopecia areata unterdupilumab, J Dtsch Dermatol Ges 2019; 17(Suppl 2):1-3.

12. Uchida H et al., Dupilumab improved alopecia areata in a patient withatopic dermatitis: a case report, Acta Derm Venereol 2019; 99:675-6.

13. Magdaleno-Tapial J et al., Improvement of alopecia areata with dupilumabin a patient with severe atopic dermatitis and review the literature,Australas J Dermatol 2019; 61(2).

14. Reinhold L et al., Haarwachstum unter dupilumab bei alopecia areatauniversalis und atopischer dermatitis, Hautarzt 2021.

15. Abercrombie M et al., Ophiasis treated with dupilumab, jaad Case Rep2021; 16:1-4.

16. Call JE et al., Effectiveness of dupilumab in the treatment of both atopicdermatitis and alopecia universalis, Clin Case Rep 2020; 8(8):1337-9.

17. Babino G et al., Rapid hair regrowth induced by dupilumab in a patientaffected by alopecia totalis of 28 years’ duration: clinical and dermoscopicfeatures, Dermatol Ther 2020; 33(4).

18. Szekely et al., Onset of Schamberg disease and resolution of alopeciaareata during treatment of atopic dermatitis with dupilumab, J InvestigAllergol Clin Immunol 2021; 31(1):65-6.

19. Harada K et al., The effectiveness of dupilumab in patients with alopeciaareata who have atopic dermatitis: a case series of seven patients,Br J Dermatol 2020; 183(2):396-7.